Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines

Investigational New Drugs

Volumn 34, Issue 3, 2016, Pages 261-268

  Flocke, Lea S ^a   Trondl, Robert ^a   Jakupec, Michael A ^a   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

ER stress; Oxidative stress; Ruthenium; Unfolded protein response

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE; RNA; RUTHENIUM DERIVATIVE; SODIUM TRANS [TETRACHLORIDOBIS(1H INDAZOLE)RUTHENATE]; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; COORDINATION COMPOUND; DDIT3 PROTEIN, HUMAN; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78; NKP-1339;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; COLON TUMOR; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COORDINATION COMPLEXES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; HEAT-SHOCK PROTEINS; HUMANS; REACTIVE OXYGEN SPECIES; TIME FACTORS; TRANSCRIPTION FACTOR CHOP;

EID: 84961217445     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0337-8     Document Type: Article

References (23)

1. Bruijnincx PC, Sadler PJ (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12:197–206
2. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK (2006) Interactions of antitumour metallodrugs with serum proteins: advances in characterisation using modern analytical methodology. Chem Rev 106:2224–2248
3. Kratz F, Keppler BK, Hartmann M, Messori L, Berger MR (1996) Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms. Metal-Based Drugs 3:15–23
4. Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G (2005) Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J Anal At Spectrom 20:856–863
5. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
6. Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Körner W, Sevelda F, Micksche M, Keppler BK, Berger W (2005) Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (FFC14A). J Pharmacol Exp Ther 312:281–289
7. Thompson DS, Weiss GJ, Jones SF, Burris HA, Ramanathan RK, Infante JR, Bendell JC, Ogden A, Von Hoff DD (2012) NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent. J Clin Oncol 30(Suppl): abstract #3033
8. Healy SJM, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A (2009) Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625:234–246
9. Szegezdi E, Logue SE, Gorman AM, Samali A (2006) Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7:880–885
10. Farooqi AA, Li KT, Fayyaz S, Chang YT, Ismail M, Liaw CC, Yuan SSF, Tang JY, Chang HW (2015) Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress. Tumour Biol 36:5743–5752
11. Van Huizen R, Martindale JL, Gorospe M, Holbrook NJ (2003) P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2α signaling. J Biol Chem 278:15558–15564
12. Peti W, Pieper T, Sommer M, Keppler BK, Giester G (1999) Synthesis of tumor-inhibiting complex salts containing the anion trans-tetrachlorobis(indazole)ruthenate(III) and crystal structure of the tetraphenylphosphonium salt. Eur J Inorg Chem 1999:1551–1555
13. Filak LK, Göschl S, Heffeter P, Ghannadzadeh Samper K, Egger AE, Jakupec MA, Keppler BK, Berger W, Arion VB (2013) Metal-arene complexes with indolo[3,2-c]-quinolines: effects of ruthenium vs osmium and modifications of the lactam unit on intermolecular interactions, anticancer activity, cell cycle, and cellular accumulation. Organometallics 32:903–914
14. Bozaykut P, Ozer NK, Karademir B (2014) Regulation of protein turnover by heat shock proteins. Free Radic Biol Med 77:195–209
15. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK, Momoi T (2007) Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Gen 16:618–629
16. Dömötör O, Hartinger CG, Bytzek AK, Kiss T, Keppler BK, Enyedy EA (2013) Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. J Biol Inorg Chem 18:9–17
17. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353:38–52
18. Kratz F (2014) A clinical update of using albumin as a drug vehicle - a commentary. J Control Release 190:331–336
19. Webb MI, Wu B, Jang T, Chard RA, Wong EWY, Wong MQ, Yapp DTT, Walsby CJ (2013) Increasing the bioavailability of RuIII anticancer complexes through hydrophobic albumin interactions. Chem Eur J 19(50):17031–17042
20. Bergamo A, Messori L, Piccioli F, Cocchietto M, Sava G (2003) Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest New Drugs 21:401–411
21. Novohradský V, Bergamo A, Cocchietto M, Zajac J, Brabec V, Mestroni G, Sava G (2015) Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. Dalton Trans 44(4):1905–1913
22. Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B (2005) The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 226:115–121
23. Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67:3496–3499